期刊文献+

多发性骨髓瘤临床分析 被引量:1

下载PDF
导出
摘要 目的了解多发性骨髓瘤的临床症状,探讨多发性骨髓瘤的临床分期,治疗方案与生存预后的关系。方法对60例多发性骨髓瘤的患者的临床治疗资料进行回顾性分析,比较DS和ISS分期的生存情况。结果分析显示DS分期的中位生存期相比没有显著统计差异,P>0.05;而ISS分期的Ⅰ期与Ⅱ/Ⅲ期的中位生存期相比却具有显著统计差异,P<0.05。经过多因素分析发现,患者年龄、CRP、骨髓浆细胞数、β2微球蛋白是影响患者生存的独立危险因素。在治疗上,VAD样治疗方案联合沙利度胺与单纯使用VAD样方案的疗效相比具有显著统计差异,P<0.01。结论与DS分期相比,ISS分期更适合中国情况。VAD样方案联合沙利度胺对治疗多发性骨髓瘤疗效比较可靠,值得临床推广应用。
作者 夏维林
出处 《中国医药指南》 2012年第1期185-185,236,共2页 Guide of China Medicine
  • 相关文献

参考文献4

二级参考文献18

  • 1陶中飞,傅卫军,陈玉宝,袁振刚,王东星,侯健.206例多发性骨髓瘤预后因素分析及分期评价[J].癌症,2006,25(4):461-464. 被引量:44
  • 2[2]Durie B G M, Salmon S E A. Clinical staging system for multiple myeloma. Cancer,1975,36:842- 854
  • 3[4]Cunninsham D, Paz- Aresl,Milian S, et al. High dose Melphalan and antologous bone marrow transplantation as consolidation in pre- viously untreated Myeloma,J,Clin Oncol 1994:12:759- 763
  • 4ALEXANDRAKIS M G, PASSAM F H, MALLIARAKI N. Evaluation of bone disease in multiple myeloma: a correlation between biochemical markers of bone metabolism and other clinical parameters in untreated multiple myeioma patients[J]. Clinica Chimi ca. Acta,2002,325:51--57.
  • 5JACOBSON J L, HUSSEIN M A, BARI.OGIE B,et al. A new staging system for multiple myeloma patients based on the Southwest Oncology Group (SWOG) experience[J]. Br J Haematol, 2003,122,441 --450.
  • 6LENTZSCH S, GRIES M, JANZ M, et al. macroPhage inflammatory Protein-1αtriggers migration and signaling cascades mediating survival and Proliferation in multiPle myeloma cells[J]. Blood ,2003,101 : 3568-- 3573.
  • 7DIMOPOULOS M A, ZERVAS K, POUI.I A, et al. Indepent validation of the Southwest Oncology Group (SWOG) staging system: a clinically useful staging system for multiple myeloma [J ]. Blood, 100,2361- 2367.
  • 8KYLE R A,GERTZ M A,WITZIG T E. Review of 1027 patients with newly diagnosed multiple myeloma [J]. Mayo Clin Proc,2003,78:21--23.
  • 9Kneller A, Rasuda P, Hardan I, et al. Therapy with thalidomide in refractory muhiple myeloma patients the revival of an old drug [ J ]. Br J Hoemato1,2000,108:391 - 3.
  • 10Hideshima T,Chanhan D, Shima Y, et al. Thalidomide and its analogs overcome drug resistance of human multiple myeloma cells to conventional therapy [ J 1. Blood,2000,96 ( 9 ) : 2943 - 50.

共引文献33

同被引文献3

引证文献1

二级引证文献6

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部